Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
AI use in schools: How districts are making sure it's used as a study aid
Recommended
How to prepare for the Fed's forthcoming interest rate cuts
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dr. Reddy's Laboratories Ltd ADR
(NY:
RDY
)
83.03
+0.76 (+0.92%)
Streaming Delayed Price
Updated: 12:47 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
55,576
Open
83.52
Bid (Size)
83.00 (1)
Ask (Size)
83.07 (2)
Prev. Close
82.27
Today's Range
83.03 - 83.56
52wk Range
63.72 - 84.46
Shares Outstanding
166,301,231
Dividend Yield
1.18%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Organon Stock Sees Relative Strength Rating Rise To 91
August 27, 2024
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before.
Via
Investor's Business Daily
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
August 24, 2024
Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with...
Via
Talk Markets
Performance
YTD
+17.22%
+17.22%
1 Month
+2.98%
+2.98%
3 Month
+18.85%
+18.85%
6 Month
+8.14%
+8.14%
1 Year
+20.75%
+20.75%
More News
Read More
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
August 20, 2024
Via
Investor's Business Daily
Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug
August 20, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr Reddy's Laboratories: Q3 Earnings Insights
January 30, 2024
Via
Benzinga
Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar
July 29, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Q1FY25 Financial Results
July 27, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
July 10, 2024
Via
MarketBeat
Should Quality-Oriented Investors Explore DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)?
July 01, 2024
Via
Chartmill
Dr. Reddy's Labs Stock Sees Improved Technical Strength
June 28, 2024
Via
Investor's Business Daily
Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M
June 26, 2024
Via
Benzinga
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
June 03, 2024
From
Aurigene Pharmaceutical Services Ltd.
Via
Business Wire
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
June 26, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High.
June 03, 2024
Via
Investor's Business Daily
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
May 28, 2024
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024
From
Alvotech
Via
GlobeNewswire
RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024
May 07, 2024
Via
InvestorPlace
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
May 07, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
May 03, 2024
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
March 19, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
February 22, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Dr. Reddy’s Q3 & 9M FY24 Financial Results
January 31, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
January 03, 2024
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
December 14, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.